Aytu Bioscience has huge potential
Aytu Bioscience Inc.(AYTU) currently trades at $1.75 and has grown by 7.43% in the past 24 hours. Aytu recently acquired Innovus Pharmaceuticals, a specialty pharmaceutical company commercializing, licensing and developing safe and effective consumer healthcare products designed to improve men and women’s health and vitality.
Based on this information, investorsQ rates this stock a 5 out of 10. We give it this rating because Aytu’s strategy is to continue building its portfolio of revenue-generating products, leveraging its focused commercial team and expertise to build leading brands within large therapeutic markets. The high forecast for Aytu Bioscience Inc. is $5 and the low is $4.75. Notably, the company’s market cap is $102.02 million with a 52 week high of $2.99 and a 52 week low of $0.34.